G1 Therapeutics Q1 2024: COSELA revenue $14.1M, net loss $10.2M, reaffirms 2024 guidance

G1 Therapeutics, Inc.

2024-Q1 EPS reported -$0.20 revenue$14,476,000

Net COSELA revenue $14.1M in Q1 2024; total revenue $14.5M, up from $12.9M YoY.
Net loss $10.2M ($0.20 per share) vs $27.6M ($0.53) in Q1 2023.
Cash and securities $65.2M; runway into Q3 2025.
Reaffirmed FY2024 COSELA net revenue guidance of $60-70M.
Phase 3 PRESERVE 2 final analysis expected late Q2 2024; Phase 2 trilaciclib+ADC data at ASCO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

G1 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $14.1 million in net product sales of COSELA, net income net loss for the first quarter of 2024 was $10.2 million, EPS $(0.20). Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $14.1 million in net product sales of COSELA
Net income: net loss for the first quarter of 2024 was $10.2 million
EPS: $(0.20)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001628280-24-019453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.